open access
Neurolymphomatosis diagnosed on [18F]FDG PET/CT
, 1, 1, 13
Affiliations- Department of Nuclear Medicine, Mohammed V Military Teaching Hospital, Rabat, Morocco
- Faculty of Medicine and Pharmacy, Cadi Ayyad University, Marrakech, Morocco
- Faculty of Medicine and Pharmacy, Mohamed V University, Rabat, Morocco
open access
Abstract
Fluorine-18-deoxyglucose positron emission tomography/computed tomography ([18F]FDG PET/CT) has been shown to be superior to other conventional imaging modalities in the detection of extra-nodal lymphomatous localizations. Especially in neurolymphomatosis which is rarely encountered in high-grade lymphomas. We report a case of a woman diagnosed with non-Hodgkin lymphoma, whose initial staging with [18F]FDG PET/CT showed increased [18F]FDG uptake along the brachial and sacral plexuses. [18F]FDG PET/CT remains the most appropriate diagnostic tool in these cases, whose prognosis is often poor.
Abstract
Fluorine-18-deoxyglucose positron emission tomography/computed tomography ([18F]FDG PET/CT) has been shown to be superior to other conventional imaging modalities in the detection of extra-nodal lymphomatous localizations. Especially in neurolymphomatosis which is rarely encountered in high-grade lymphomas. We report a case of a woman diagnosed with non-Hodgkin lymphoma, whose initial staging with [18F]FDG PET/CT showed increased [18F]FDG uptake along the brachial and sacral plexuses. [18F]FDG PET/CT remains the most appropriate diagnostic tool in these cases, whose prognosis is often poor.
Keywords
neurolymphomatosis; FDG-PET/CT; non-Hodgkin lymphoma
About this articleTitle
Neurolymphomatosis diagnosed on [18F]FDG PET/CT
Journal
Issue
Vol 26 (2023): Continuous Publishing
Article type
Clinical vignette
Pages
96-97
Published online
2023-07-13
Page views
1082
Article views/downloads
242
DOI
Bibliographic record
Nucl. Med. Rev 2023;26:96-97.
Keywords
neurolymphomatosis
FDG-PET/CT
non-Hodgkin lymphoma
Authors
Yassir Benameur
Omar Ait Sahel
Salah Nabih Oueriagli
Abderrahim Doudouh
References (6)- Gan HK, Azad A, Cher L, et al. Neurolymphomatosis: diagnosis, management, and outcomes in patients treated with rituximab. Neuro Oncol. 2010; 12(2): 212–2015.
- Baehring JM, Damek D, Martin EC, et al. Neurolymphomatosis. Neuro Oncol. 2003; 5(2): 104–115.
- Kajáry K, Molnár Z, Mikó I, et al. Neurolymphomatosis as a late relapse of non-Hodgkin's lymphoma detected by 18F-FDG PET/CT: a case report. Rev Esp Med Nucl Imagen Mol. 2014; 33(1): 39–42.
- Cheung C, Lopes D, Hung KN, et al. Neurolymphomatosis: role of positron emission tomography in diagnosis. Ann Hematol. 2012; 91(8): 1313–1314.
- Baehring JM, Batchelor TT. Diagnosis and management of neurolymphomatosis. Cancer J. 2012; 18(5): 463–468.
- Narita K, Terao T, Tsushima T, et al. Clinical features, diagnosis, and prognosis of 22 cases of neurolymphomatosis : a single-institution experience over 12 years. Blood. 2019; 134(Supplement_1): 1630–1630.
